Scrip Symbol

SUVEN

Suven Life Sciences Limited announced positive topline results from its Phase-2b clinical proof-of-concept trial of Ropanicant (SUVN-911) for the treatment of Major Depressive Disorder (MDD). Ropanicant is an investigational nicotinic α4β2 receptor antagonist.

Trial Results and Statistical Significance

The Phase-2b trial demonstrated that Ropanicant 45 mg administered twice daily resulted in clinically meaningful improvement in the Montgomery–Åsberg Depression Rating Scale (MADRS) total score compared with placebo at Week 6, which was the primary endpoint.

The maximum likelihood-estimated mean difference from baseline versus placebo was:

  • -3.572 in the Full Analysis Set (p = 0.038)
  • -3.570 in the modified Full Analysis Set (p = 0.038)
  • -4.067 in the Per-Protocol Set (p = 0.023)

Evidence of treatment benefit was observed across secondary endpoints including Clinical Global Impression–Severity of Illness (CGI-S; p = 0.094) and the Sheehan Disability Scale (SDS; p = 0.039), as well as the exploratory Quality of Life in Depression Scale (QLDS; p = 0.068).

Safety and Tolerability

Ropanicant was generally well tolerated in patients with MDD. The majority of treatment-emergent adverse events (TEAEs) were mild to moderate in severity, with no unexpected safety signals identified. Most adverse events were transient and resolved without clinically significant intervention.

No clinically meaningful changes were identified in:

  • Clinical laboratory parameters (haematology, clinical chemistry, urinalysis)
  • Electrocardiogram (ECG) parameters
  • Vital signs (blood pressure, heart rate, respiratory rate, body weight, body temperature)
  • Physical examination findings

No withdrawal symptoms were observed after discontinuation of Ropanicant treatment, and there was no evidence of Dissociation.

Trial Design and Execution

The study was a randomized, double-blind, placebo-controlled trial that enrolled 214 patients across 35 sites in the United States of America for a treatment duration of six weeks. The study evaluated the efficacy and safety of Ropanicant 45 mg or 30 mg administered twice daily compared with placebo. The ClinicalTrials.gov identifier is NCT06836063.

Intellectual Property and Future Plans

Suven fully owns all intellectual property rights for Ropanicant in all major markets. A priority patent application has already been filed, and an International Application claiming priority will be filed in a few days.

The company is planning a global Phase-3 registrational study in MDD. Detailed findings from the clinical study will be presented in future medical conferences and/or peer-reviewed journal publications.

Management Commentary

Mr. Venkat Jasti, Chairman and Managing Director, stated that the results demonstrate Ropanicant's potential as a promising treatment for MDD and that it would offer a differentiated treatment option to meet unmet medical needs.

Mr. Ramakrishna Nirogi, President and CSO, noted that MDD is the leading cause of disability worldwide and approximately 50% of patients do not adequately benefit from standard first-line antidepressant therapies. The Phase-2b data strongly supports the potential of Ropanicant as a promising treatment.

Company Background

Suven Life Sciences Limited is a clinical-stage biopharmaceutical company focused on discovering and developing innovative treatments for Central Nervous System (CNS) disorders. The company has a portfolio of advanced stage clinical candidates and research programs for CNS disorders including Alzheimer's disease, Sleep disorders, Major depressive disorders, Parkinson's disease, Schizophrenia, Pain disorders, and Gastrointestinal disorders.